BioGend Therapeutics Co., Ltd. Stock Price

TPEX:6733 Community·NT$4.1b Market Cap

0 Narratives written by author
0 Comments on narratives written by author
0 Fair Values set on narratives written by author

Create a narrative

6733 Share Price Performance

NT$32.80

4.25 (14.89%)

NT$32.80

4.25 (14.89%)

NT$32.80

Fri, 3 Apr 26

Share Pricen/a

6733 Community Narratives

There are no narratives available yet.

Create a narrative

There are no community narratives available.

Trending Discussion

Snowflake Analysis

Excellent balance sheet and overvalued.

0 Risks

1 Reward

View Full Analysis

BioGend Therapeutics Co., Ltd. Key Details

Last Reported Earnings

Dec 31, 2025

Next Reporting Earnings

n/a

: -0.68
: 72.03%
: -38.05%
: 0%

View Full Analysis

About 6733

Founded: 2016
Employees: n/a
CEO: Te-Li Chen
WebsiteView website: www.biogend.com

BioGend Therapeutics Co., Ltd. engages in the research and development, and sale of orthopedic medical devices and related products. The company offers RevoCart, an autologous cartilage repair system; and SoufCut, an autologous adipose tissue collection system. It develops BiG-001, an osteoinductive bone graft substitute; BiG-006 for lumbar interbody fusion; and BiG-009, an autologous cartilage repair system for articaular cartilage. The company operates in Taiwan, Hongkong, Chinese Mainland, and Malaysia. BioGend Therapeutics Co., Ltd. was founded in 2016 and is based in Taipei, Taiwan.